

Bladder Cancer (Urothelial) Pathways

Patient Name: _____ **Date of Birth:** _____

Member ID: _____ **Treatment Start Date:** _____

Stage: _____ **Pathology:** _____

ECOG Status: 1 2 3 4 **ICD-10 Code:** _____

Line of Therapy:

Neoadjuvant/Pre-op Adjuvant/Post Op 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Goal of Treatment: Curative Non-Curative

Biomarkers/Attributes: (select all that apply)

Microsatellite instability:	<input type="checkbox"/>	dMMR/MSI-H	<input type="checkbox"/>	MSI-L	<input type="checkbox"/>	Not Reported	NTRK Fusion: <input type="checkbox"/> Positive <input type="checkbox"/> Negative
Platinum Resistant/Refractory:	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>	Not Reported	

* Platinum resistant is defined as recurrence of less than 6 months after prior platinum-based therapy

Neoadjuvant/Adjuvant:

Non-muscle invasive

- Intravesical BCG (Bacillus Calmette-Guerin)
- Intravesical gemcitabine

Muscle Invasive

- Gemcitabine + Cisplatin
- Cisplatin + Methotrexate + Vinblastine (CMV)

Radio-sensitizing chemotherapy for organ-preserving chemoradiation:

- Cisplatin + Fluorouracil (5FU)
- Gemcitabine

Locally Advanced or Metastatic:

1st line of therapy

- Gemcitabine + Cisplatin or Carboplatin

Maintenance post 1st line of therapy and no progression

- Avelumab

2nd line of therapy

- Pembrolizumab (if IO not used previously)
- Nivolumab (if IO not used previously)
- Avelumab (if IO not used previously)
- Gemcitabine + Cisplatin or Carboplatin (if platinum-based therapy not used previously)

3rd + subsequent line of therapy

- Enfortumab vedotin-ejfv
- Gemcitabine + Cisplatin or Carboplatin (if platinum-based therapy not used previously)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



References:

- Addeo R, Caraglia M, Bellini S, et al; Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. *J Clin Oncol*. 2010 Feb 1;28(4):543-8. Doi: 10.1200/JCO.2008.20.8199. Epub 2009 Oct 19. PMID: 19841330.
- Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol*. 2005 Aug;48(2):202-5; discussion 205-6. doi: 10.1016/j.eururo.2005.04.006. Epub 2005 Apr 21. PMID: 15939524.
- Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. *J Clin Oncol*. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4. PMID: 28375787; PMCID: PMC5493051.
- Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442. PMID: 34077643; PMCID: PMC8215888.
- Balar AV, Galsky MD, Rosenberg JE, et al; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: *Lancet*. 2017 Aug 26;390(10097):848. PMID: 27939400; PMCID: PMC5568632.
- Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med*. 2017 Mar 16;376(11):1015-1026. Doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. PMID: 28212060; PMCID: PMC5635424.
- Bellmunt J, Hussain M, Gschwend JE, et al; IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021 Apr;22(4):525-537. doi: 10.1016/S1473-2045(21)00004-8. Epub 2021 Mar PMID: 33721560.
- Böhle A, Bock PR. Intravesical Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. *Urology*. 2004 Apr;63(4):682-6; discussion 686-7. Doi: 10.1016/j.urology.2003.11.049. PMID: 15072879.
- Calabrò F, Lorusso V, Rosati G, Manzione L, Frassinetti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. *Cancer*. 2009 Jun 15;115(12):2652-9. doi: 10.1002/cncr.24313. PMID: 19396817.
- Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. *J Clin Oncol*. 2011 Feb 20;29(6):733-8. doi: 10.1200/JCO.2010.31.5721. Epub 2011 Jan 4. PMID: 21205754.
- Choueiri TK, Jacobus S, Bellmunt J, et al; Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *J Clin Oncol*. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12. PMID: 24821883; PMCID: PMC7057274.
- Coen JJ, Zhang P, Saylor PJ, et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. *J Clin Oncol*. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15. Erratum in: *J Clin Oncol*. 2021 Apr 10;39(11):1309. PMID: 30433852; PMCID: PMC6354769.
- Dash A, Pettus JA 4th, Herr HW, et al; A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. *Cancer*. 2008 Nov 1;113(9):2471-7. doi: 10.1002/cncr.23848. PMID: 18823036; PMCID: PMC2585515.
- de Reijke TM, Kurth KH, Sylvester RJ, et al; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus almette n for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer—Genito-Urinary Group Phase III Trial (30906). *J Urol*. 2005 Feb;173(2):405-9. Doi: 10.1097/01.ju.0000150425.09317.67. PMID: 15643181.
- Flaig TW, Tangen CM, Daneshmand S, et al; Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). *Clin Cancer Res*. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10. PMID: 33568346; PMCID: PMC8219246.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Galsky MD, Ariba J, Bamias A, et al; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0. PMID: 32416780.

Galsky MD, Pal SK, Chowdhury S, et al; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. *Cancer*. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14. PMID: 25872978.

Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *NEJM* 2003;349:859-866.

International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. *J Clin Oncol*. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr PMID: 21502557; PMCID: PMC3107740.

James ND, Hussain SA, Hall E, et al; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *N Engl J Med*. 2012 Apr 19;366(16):1477-88. doi:10.1056/NEJMoa1106106. PMID: 22512481.

Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. *J Clin Oncol*. 2004 Jul 1;22(13):2540-5. doi: 10.1200/JCO.2004.10.070. PMID: 15226322.

Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer* 2015;15:25-41.

Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. *J Urol*. 2000;163(4):1124-9. PMID: 10737480

Li Q, Bagrodia A, Cha EK, Coleman JA. Prognostic genetic signatures in upper tract urothelial carcinoma. *Curr Urol Rep* 2016;17:12-12.

Loriot Y, Necchi A, Park SH, et al; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med*. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. PMID: 31340094.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. *J Clin Oncol*. 1997 May;15(5):1853-7. Doi: 10.1200/JCO.1997.15.5.1853. PMID: 9164195.

Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. *Lancet Oncol*. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1. PMID: 23823157; PMCID: PMC3955198.

National Cancer Institute. Cancer Statistics. Retrieved from <https://seer.cancer.gov/statfacts/html/urinb.html> National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Accessed Aug 30, 2021. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol*. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5. Erratum in: *Lancet Oncol*. 2018 Jul;19(7):e335. PMID: 29217288; PMCID: PMC7984727.

Pfister C, Gravis G, Fléchon A, et al; VESPER Trial Investigators. Randomized Phase III Trial of Dosedense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. *Eur Urol*. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. PMID: 32868138.

Plimack ER, Hoffman-Censits JH, Viterbo R, et al; Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. *J Clin Oncol*. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12. PMID: 24821881; PMCID: PMC4050203.

Powles T, Csósz T, Özgüroğlu M, et al; KEYNOTE-361 Investigators. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE361): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. PMID: 34051178.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: *Lancet*. 2018 Oct 20;392(10156):1402. PMID: 29268948.

Powles T, Park SH, Voog E et al. Avelumab maintenance + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. *N Engl J Med* 2020; 383:1218-30.

Powles T, Rosenberg JE, Sonpavde G, et al: Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. 2021 Genitourinary Cancers Symposium. Abstract 393. Presented February 12, 2021.\

Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. PMID: 28131785.

Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. *BJU Int*. 2004;93(4):485-90. PMID: 15008714

Sideris S, Aoun F, Zanaty M, et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. *Mol Clin Oncol*. 2016 Jun;4(6):1063-1067. Doi: 10.3892/mco.2016.821. Epub 2016 Mar 17. PMID: 27284445; PMCID: PMC4887921.

Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. *Cancer*. 2013 Feb 1;119(3):540-7. doi: 10.1002/cncr.27751. Epub 2012 Aug 22. PMID: 22914978; PMCID: PMC3828072.

Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. *J Clin Oncol*. 1997 Nov;15(11):3394-8. Doi: 10.1200/JCO.1997.15.11.3394. PMID: 9363871.

Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. *Eur J Cancer*. 2006 Jan;42(1):50-4. doi: 10.1016/j.ejca.2005.08.032. Epub 2005 Dec 5. PMID: 16330205.

Sternberg CN, de Mulder PH, Schornagel JH, et al; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. *J Clin Oncol*. 2001 May 15;19(10):2638-46. doi: 10.1200/JCO.2001.19.10.2638. PMID: 11352955.

Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol*. 2005 Jul;174(1):86-91; discussion 91-2. Doi: 10.1097/01.ju.0000162059.64886.1c. PMID: 15947584.18

Tagawa ST, Balar AV, Petrylak DP, et al; TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. *J Clin Oncol*. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30. PMID: 33929895; PMCID: PMC8315301

Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. *J Clin Oncol*. 1996 Jan;14(1):119-26. doi: 10.1200/JCO.1996.14.1.119. PMID: 8558186.

von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol*. 2000 Sep;18(17):3068-77. doi: 10.1200/JCO.2000.18.17.3068. PMID: 11001674.

Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. *J Clin Oncol*. 2020 Aug 10;38(23):2658-2666. doi:10.1200/JCO.19.01213. Epub 2020 Jun 17. PMID: 32552471.

Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath El, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2021 Jun;22(6):872-882. Doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Erratum in: *Lancet Oncol*. 2021 Jun;22(6):e239. PMID: 33991512.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur Urol*. 2015 Feb;67(2):241-9. doi: 10.1016/j.eururo.2014.09.007. Epub 2014 Sep PMID: 25257030; PMCID: PMC4840190.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Last Review [2.18.2022] | Effective [3.1.2022]